PuSH - Publikationsserver des Helmholtz Zentrums München

Lomeguatrib increases the radiosensitivity of mgmt unmethylated human glioblastoma multiforme cell lines.

Int. J. Mol. Sci. 22:6781 (2021)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Background: Treatment resistance of glioblastoma multiforme to chemo-and radiotherapy remains a challenge yet to overcome. In particular, the O6-methylguanine-DNA-methyltransferase (MGMT) promoter unmethylated patients have only little benefit from chemotherapy treatment using temozolomide since MGMT counteracts its therapeutic efficacy. Therefore, new treatment options in radiotherapy need to be developed to inhibit MGMT and increase radiotherapy response. Methods: Lomeguatrib, a highly specific MGMT inhibitor, was used to inactivate MGMT protein in vitro. Radiosensitivity of established human glioblastoma multiforme cell lines in combination with lomeguatrib was investigated using the clonogenic survival assay. Inhibition of MGMT was analyzed using Western Blot. Cell cycle distribution and apoptosis were investigated to determine the effects of lomeguatrib alone as well as in combination with ionizing radiation. Results: Lomeguatrib significantly decreased MGMT protein and reduced radiation-induced G2/M arrest. A radiosensitizing effect of lomeguatrib was observed when administered at 1 µM and increased radioresistance at 20 µM. Conclusion: Low concentrations of lomeguatrib elicit radiosensitization, while high concentrations mediate a radioprotective effect.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
5.923
1.441
1
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Glioblastoma ; Lomeguatrib ; Mgmt ; Radiosensitivity ; Radiotherapy; Temozolomide Plus O-6-benzylguanine; Central-nervous-system; Recurrent; Alkyltransferase; Inactivation; Resistance; Cycle; Dna; Repair; Glioma
Sprache englisch
Veröffentlichungsjahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 1661-6596
e-ISSN 1422-0067
Quellenangaben Band: 22, Heft: 13, Seiten: , Artikelnummer: 6781 Supplement: ,
Verlag MDPI
Verlagsort Basel
Begutachtungsstatus Peer reviewed
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Radiation Sciences
PSP-Element(e) G-501300-001
Förderungen Medical Faculty of TUM
German Consortium for Translational Cancer Research
Scopus ID 85108420303
PubMed ID 34202589
Erfassungsdatum 2021-07-02